ABSK-011 is named as a drug or biological intervention in 3 clinical trials in our China and USA trial registers, 2 of which are recruiting. The lead sponsor is Abbisko Therapeutics Co, Ltd. Registered phases: Phase 1 and Phase 2. Conditions studied include Advanced Liver Cancer; Healthy Participants; Hepatocellular Carcinoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04906434 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor (ClinicalTrials.gov ↗) Advanced Liver Cancer |
Phase 1 | Recruiting |
| NCT07700953 | A Study to Evaluate the Effects of Low-Fat Meal, High-Fat Meal and Omeprazole Enteric-Coated Tablets on the Pharmacokinetics of ABSK-011 Capsules in Healthy Participants (ClinicalTrials.gov ↗) Healthy Participants |
Phase 1 | Recruiting |
| NCT05441475 | A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients (ClinicalTrials.gov ↗) Hepatocellular Carcinoma |
Phase 2 | By invitation |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Liver Cancer | 1 |
| Healthy Participants | 1 |
| Hepatocellular Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Abbisko Therapeutics Co, Ltd | 3 |
| Register | ABSK-011 trials |
|---|---|
| Clinical trials in China | 3 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ABSK-011 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ABSK-011 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.